Stockscreener 앱 받기
2.18
0.46%
-0.010
시간 외 거래:
2.18
전일 마감가:
$2.19
열려 있는:
$2.17
하루 거래량:
40,103
Relative Volume:
0.88
시가총액:
$23.40M
수익:
$62.64M
순이익/손실:
$-24.56M
주가수익비율:
-0.5679
EPS:
-3.8387
순현금흐름:
$-3.70M
1주 성능:
+4.81%
1개월 성능:
-13.49%
6개월 성능:
+3.81%
1년 성능:
+11.22%
1일 변동 폭
$2.105
$2.19
1주일 범위
$2.03
$2.19
52주 변동 폭
$1.46
$3.065
Aytu Biopharma Inc Stock (AYTU) Company Profile
명칭
Aytu Biopharma Inc
전화
(720) 437-6580
주소
7900 E. UNION AVENUE, DENVER
Compare AYTU vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.18 | 23.51M | 62.64M | -24.56M | -3.70M | -3.8387 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.61 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.23 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-01 | 개시 | Lake Street | Buy |
| 2025-06-30 | 개시 | Ascendiant Capital Markets | Buy |
| 2021-03-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-29 | 개시 | H.C. Wainwright | Buy |
Aytu Biopharma Inc 주식(AYTU)의 최신 뉴스
Aytu BioPharma Q1 2026 Earnings: EPS Misses Estimates Despite Positive Stock MovementDiluted EPS Report - Newser
Earnings call transcript: Aytu BioPharma Q3 2026 reveals earnings miss By Investing.com - Investing.com Nigeria
Earnings call transcript: Aytu BioPharma Q3 2026 reveals earnings miss - Investing.com
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - ACCESS Newswire
Pharma firm Aytu BioPharma to present at virtual investor event May 28 - Stock Titan
Aytu outlines $6M-$7M quarterly sales and marketing spend range as EXXUA scripts rise to over 920 in April - MSN
Aytu BioPharma to Participate in September 2022 Investor Conferences - The Chronicle-Journal
Aytu BioPharma, Inc.Common Stock (NQ: AYTU - The Chronicle-Journal
What Aytu Bio AYTU is doing that separates it from the herd Institutional Selling 20260507Expert Trade Signals - Newser
Analysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before Long - Sahm
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2026 Earnings Call Transcript - Insider Monkey
AYTU BIOPHARMA INC | BIG RISK REWARD | AYTU STOCK | AYTU BIOPHARMA STOCK (K8VNph4cYO) - fathomjournal.org
Aytu BioPharma, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
Aytu BioPharma Inc (AYTU) Q3 2026 Earnings Call Highlights: Stro - GuruFocus
Is Aytu BioPharma (AYTU) Overvalued After Q3 FY2026 Earnings Mis - GuruFocus
Aytu (AYTU) Reports Strong Q3 Revenue and Positive Launch Moment - GuruFocus
Aytu BioPharma, Inc. (AYTU) reports Q3 loss, tops revenue estimates - MSN
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates - sharewise.com
AYTU: EXXUA's launch drove strong early growth, with over 1,300 prescriptions and $2.4M in revenue - TradingView
Aytu Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aytu (AYTU) Q3 2026 Earnings Transcript - The Globe and Mail
Full Transcript: Aytu BioPharma Q3 2026 Earnings Call - Yahoo Finance
Aytu BioPharma (NASDAQ:AYTU) Surges 23% as EXXUA Launch Gains Early Traction in Mixed Q3 Results - ChartMill
Aytu BioPharma Q3 revenue falls amid EXXUA launch - TradingView
AYTU BIOPHARMA Q3 EPS USD -0.53 - Moomoo
Aytu BioPharma (AYTU) swings to loss while launching EXXUA and cutting warrant liabilities - Stock Titan
EXXUA launch reshapes Aytu BioPharma (Nasdaq: AYTU) Q3 2026 results - Stock Titan
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results - ChartMill
Aytu's EXXUA depression pill earns $2.4M in $22B MDD market - Stock Titan
MSN Money - MSN
Aytu BioPharma Q3 Earnings Announcement Scheduled - Intellectia AI
Aytu Biopharma Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
AYTU: Aytu BioPharma, Inc.Interactive Chart - Zacks Investment Research
What Aytu Bio (AYTU) is doing that separates it from the herd (Institutional Selling) 2026-05-07AI Powered Stock Picks - newser.com
Number of shareholders of Aytu BioPharma, Inc. – LS:A3D38R - TradingView
Aytu BioPharma sets May 13 Q3 2026 results call after close - Stock Titan
Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026 - ACCESS Newswire
Favourable Signals For Aytu BioPharma: Numerous Insiders Acquired Stock - Yahoo Finance
Aytu BioPharma, Inc. (AYTU) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
EPS Watch: Is Aytu BioPharma Inc forming a double bottom2026 Stock Rankings & Reliable Entry Point Trade Alerts - baoquankhu1.vn
AYTU Stock Analysis: Aytu BioPharma Inc. biotech stock at 2.68 posts 1.52 percent daily gain - Cổng thông tin điện tử tỉnh Lào Cai
Aytu BioPharma amends warrants to address accounting classification - Investing.com
Aytu BioPharma amends warrants to address accounting classification By Investing.com - Investing.com Canada
Aytu BioPharma Amends Investor Warrants to Restore Equity Classification and Reduce Liabilities - TradingView — Track All Markets
Aytu BioPharma (NASDAQ: AYTU) rewrites warrant terms to restore equity - Stock Titan
Aytu Biopharma Inc (AYTU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aytu Biopharma Inc 주식 (AYTU) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Disbrow Joshua R. | Chief Executive Officer |
Jun 09 '25 |
Buy |
1.50 |
66,666 |
99,999 |
153,257 |
5.02%
5.78%
자본화:
|
볼륨(24시간):